🔬 Expanding our integrated capabilities in autoimmune research
September 3, 2025

At Pharmidex, we are proud to offer a comprehensive preclinical platform for autoimmune disease research.


Using in vivo EAE models, we combine:

 ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression

 ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs

 ✔️ Pharmacological intervention studies, including established treatments


This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation.


By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects.


👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.

Expanding our integrated capabilities in autoimmune research
December 8, 2025
Head of Respiratory at Pharmidex , Ian Knowles will be attending the Drug Delivery to the Lungs Conference (DDL) on 10–12 December 2025 at the Edinburgh International Conference Centre. DDL brings together global leaders in pulmonary and respiratory drug delivery, and Ian looks forward to meeting fellow attendees, exploring collaborations, and discussing how Pharmidex can support and accelerate drug discovery and development across industry and academia. If you’ll be there too, feel free to reach out we look forward to building new connections and advancing innovation together.
December 3, 2025
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) and Janette Dalay Robertson will attend the “Recent Clinical Candidates and SMR Award Meeting” this Thursday, 4 December 2025. If you’re attending, we’d be happy to connect!
December 2, 2025
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) , and our Dr. Ian Knowles , will attend Genesis 2025 this Wednesday, December 3rd, hosted by One Nucleus . They look forward to meeting fellow attendees, exploring new collaborations, and building partnerships with companies and academic groups to advance drug discovery and development. See you at Genesis 2025!
More Posts